Nirrin files to raise $9.7M for bioprocess analytics tools
What's the deal? Nirrin Technologies has filed a notice with the Securities and Exchange Commission for an early-stage venture round of up to $9,711,196. The filing, dated July 2026, discloses an exempt securities offering under Regulation D.
What's the endgame? Nirrin builds bioprocess analytics tools using high-precision tunable laser spectroscopy. Its systems deliver direct, quantitative measurements from drug development through manufacturing.
What does it make? The company sells two products: TALOS, which handles protein quantitation without dilution or calibration curves, and ATLAS, which measures multiple analytes — proteins, buffers, and excipients — in complex samples. The pitch is simpler workflows and more reliable data for bioprocess teams.
A Regulation D notice must be filed within 15 days of a round's first sale, so the capital may already be partly committed.
The signal: At roughly $9.7 million, the round sits in the top quartile for early-stage venture deals by size, a signal of investor appetite for analytics tools serving biopharma manufacturing. The filing points to continued backing for companies solving measurement and quality-control problems in drug production.
Read more: Intelligence360 News
